STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Appoints Adam Keeney as Head of Corporate Development
management
IMPACT
SENTIMENT
BIIB : Nasdaq
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
IMPACT
SENTIMENT
BIIB : Nasdaq
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Appoints Chuck Triano as Head of Investor Relations
management
IMPACT
SENTIMENT
BIIB : Nasdaq
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
management
IMPACT
SENTIMENT
SAGE : Nasdaq BIIB : Nasdaq
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#418 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili